When the cardiac and neurovascular catheterization lab at Riverside University Health System Medical Center (RUHS-MC) treated its first patient last February, the opening represented many things to many people.

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.

Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

The transcarotid approach to TAVR is becoming more common, according to research presented at TVT.19.

Sometimes a move in the right direction starts with a good hard look in the rearview mirror, then breaking it off to start anew with greater wisdom.

Medical directors of cardiac catheterization and EP labs receive three to four times the amount of money from pharmaceutical companies and device manufacturers as other interventional cardiologists in the same zip code, according to a JAMA Internal Medicine study.